sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Multiplexed Diagnostics Market Size study, by Product Type, by Application, by End User and Regional Forecasts 2022-2032

Global Multiplexed Diagnostics Market Size study, by Product Type, by...

Home / Categories / Healthcare
Global Multiplexed Diagnostics Market Size study, by Product Type, by Application, by End User and Regional Forecasts 2022-2032
Global Multiplexed Diagnostics Market Size...
Report Code
RO1/103/2835

Publish Date
13/Aug/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
Global Multiplexed Diagnostics Market is valued approximately at USD 14.03 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 14.5% over the forecast period 2024-2032. Multiplexing refers to the simultaneous detection or identification of multiple biomarkers within a single diagnostic test, presenting immense value for diagnosing a plethora of diseases. This capability is particularly significant for detecting and identifying the most common causes of infectious diseases directly from clinical specimens, benefiting patient care, hospital infection control practices, and epidemiologic studies. The market for multiplexed diagnostics has experienced notable growth due to the increasing prevalence of chronic diseases such as infectious diseases, cardiac disorders, and respiratory and allergic conditions, necessitating precise diagnostics for multiple biomarkers or analytes in a single assay. This reduces time and resource consumption compared to performing individual tests, thus driving market expansion.

The shift towards personalized medicine, which necessitates customized treatments based on individual genetic profiles, further fuels the demand for multiplexed diagnostics. Technological advancements, including the development of microarrays, bead-based assays, and next-generation sequencing, have significantly broadened the scope of multiplexed diagnostics, enabling the identification of various biomarkers with enhanced precision. Moreover, the rising number of key market players focusing on improving their product portfolios through strategic partnerships and innovations propels market growth. For instance, in January 2023, Agilent Technologies, Inc. partnered with Akoya Biosciences, Inc. to develop multiplex-immunohistochemistry diagnostic solutions for tissue analysis, integrating their respective technologies to create a comprehensive commercial workflow. Additionally, multiplexed diagnostics play a crucial role in drug development and clinical trials by providing insights into biomarker profiles, patient stratification, and treatment responses, accelerating the development of new therapies. The increase in R&D activities globally and collaborations between diagnostic companies, pharmaceutical firms, and research institutions have led to the development of multiplexed assays with both diagnostic and therapeutic applications, creating lucrative opportunities for market growth. However, high costs associated with multiplexed diagnostic ad data privacy and cybersecurity concerns are factors hindering the market growth.

The key regions considered for the Global Multiplexed Diagnostics market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America accounted for a major share of the multiplexed diagnostics market in 2023 and is expected to maintain its dominance during the forecast period. This dominance is attributed to the presence of key players, rising prevalence of chronic and infectious diseases, and significant R&D activities in multiplexed diagnostics. For instance, PerkinElmer offers a range of diagnostic and research solutions, including multiplexed assays for biomarker discovery and validation, contributing to regional market growth. Asia-Pacific is expected to grow at the fastest rate during the forecast period, driven by increasing healthcare IT spending and expanding healthcare infrastructure in developing countries such as China, India, and Japan.

Major market players included in this report are:
Siemens Healthineers AG
DiaSorin S.p.A.
Illumina Inc.
F. Hoffmann-La Roche Ltd.
Co-Diagnostics, Inc.
Bio-Rad Laboratories Inc.
Thermo Fisher Scientific Inc.
Hologic Inc.
Agilent Technologies, Inc.
BioMerieux SA
PerkinElmer Inc.
Luminex Corporation
Seegene Inc.
Becton, Dickinson and Company
Merck KGaA
The detailed segments and sub-segment of the market are explained below:
By Product Type:
Instruments and Accessories
Kits and Reagents
By Application:
Infectious Disease
Oncology
Autoimmune Diseases
Cardiac Diseases
Allergies
Others
By End User:
Hospitals
Diagnostic Centers
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
South Africa
Saudi Arabia
Rest of Middle East and Africa
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com